Antiva wants to help treat cervical cancer. Most male investors aren't interested.
 
 
A young pharmaceutical startup wants to develop a groundbreaking new treatment for a relatively common cancer. Yet it struggles to find funding.
That's because the startup in question is Antiva Biosciences, and the cancer it aims to treat is cervical cancer. Stat reported Thursday on the company's struggles to attract investment, as well as its constant fight to receive buy-in from male doctors, quoting Antiva's top executives discussing frankly their perceptions of the problem: "It's very safe to say that we got more traction in [venture capital] firms where there was a woman partner who was in a decision-making role," Antiva CEO Gail Maderis told Stat.
Antiva's proposal is to replace the most common treatment prescribed for women who develop the precancerous cervical lesions that result from being infected with HPV, which is surgery. The operation removes the lesions by "essentially cutting off the tip of the cervix," Stat reports. The surgery has proven effective in eradicating the problem cells, but "women of childbearing age who undergo the surgery may later have difficulty conceiving, recurrent miscarriages, and preterm delivery," Stat explains.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
 
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Antiva says about 500,000 women undergo this procedure every year. Instead of surgery, the company is proposing a topical treatment that patients can administer themselves. But the reception has been lukewarm: Maderis told Stat of how one prospective male investor who appeared unenthused during Maderis' pitch. But after their meeting, he called Maderis to explain how his wife had pressed him to investigate the deal further after he'd told her about the company's mission.
One man, David Kabakoff, did invest in Antiva through his firm. His team has been calling gynecologists to glean their reactions to the topical treatment. "The trend was unmistakable," Stat wrote: "Male physicians tended to express skepticism ... Female physicians tended to say new treatment options are badly needed." Read more about Antiva at Stat.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kimberly Alters is the news editor at TheWeek.com. She is a graduate of the Medill School of Journalism at Northwestern University.
- 
 Warner Bros. explores sale amid Paramount bids Warner Bros. explores sale amid Paramount bidsSpeed Read The media giant, home to HBO and DC Studios, has received interest from multiple buying parties 
- 
 Gold tops $4K per ounce, signaling financial unease Gold tops $4K per ounce, signaling financial uneaseSpeed Read Investors are worried about President Donald Trump’s trade war 
- 
 Electronic Arts to go private in record $55B deal Electronic Arts to go private in record $55B dealspeed read The video game giant is behind ‘The Sims’ and ‘Madden NFL’ 
- 
 New York court tosses Trump's $500M fraud fine New York court tosses Trump's $500M fraud fineSpeed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth 
- 
 Trump said to seek government stake in Intel Trump said to seek government stake in IntelSpeed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting 
- 
 US to take 15% cut of AI chip sales to China US to take 15% cut of AI chip sales to ChinaSpeed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China 
- 
 NFL gets ESPN stake in deal with Disney NFL gets ESPN stake in deal with DisneySpeed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network 
- 
 Samsung to make Tesla chips in $16.5B deal Samsung to make Tesla chips in $16.5B dealSpeed Read Tesla has signed a deal to get its next-generation chips from Samsung 



